# Navitas Semiconductor Corp: financial statements, quarterly

NVTS · Nasdaq · CIK 1821769 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nvts.md) · [Financials](/companies/nvts/financials.md) · [Filings](/companies/nvts/filings.md) · [Insiders](/companies/nvts/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nvts/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [22.0](/filings/0001821769-24-000122.md) | [26.1 d](/filings/0001821769-25-000021.md) | [23.2](/filings/0001821769-25-000068.md) | [20.5](/filings/0001821769-25-000181.md) | [21.7](/filings/0001821769-25-000214.md) | [18.0 d](/filings/0001821769-26-000007.md) | [14.0](/filings/0001628280-26-030524.md) | [14.5](/filings/0001628280-26-049808.md) | [10.1](/filings/0001821769-25-000214.md) | [7.3 d](/filings/0001821769-26-000007.md) | [8.6](/filings/0001628280-26-030524.md) | [10.5](/filings/0001628280-26-049808.md) |
| Cost of revenue | $m | [14.9](/filings/0001821769-24-000122.md) | [15.1 d](/filings/0001821769-25-000021.md) | [13.7](/filings/0001821769-25-000068.md) | [12.5](/filings/0001821769-25-000181.md) | [13.1](/filings/0001821769-25-000214.md) | [15.8 d](/filings/0001821769-26-000007.md) | [8.7](/filings/0001628280-26-030524.md) | [12.2](/filings/0001628280-26-049808.md) | [6.3](/filings/0001821769-25-000214.md) | [4.5 d](/filings/0001821769-26-000007.md) | [5.4](/filings/0001628280-26-030524.md) | [6.5](/filings/0001628280-26-049808.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [16.6](/filings/0001821769-24-000122.md) | [18.1 d](/filings/0001821769-25-000021.md) | [20.2](/filings/0001821769-25-000068.md) | [19.0](/filings/0001821769-25-000181.md) | [17.8](/filings/0001821769-25-000214.md) | [19.0 d](/filings/0001821769-26-000007.md) | [12.7](/filings/0001628280-26-030524.md) | [11.5](/filings/0001628280-26-049808.md) | [13.3](/filings/0001821769-25-000214.md) | [12.4 d](/filings/0001821769-26-000007.md) | [14.6](/filings/0001628280-26-030524.md) | [13.2](/filings/0001628280-26-049808.md) |
| Selling, general and administrative | $m | [14.4](/filings/0001821769-24-000122.md) | [14.9 d](/filings/0001821769-25-000021.md) | [16.1](/filings/0001821769-25-000068.md) | [15.4](/filings/0001821769-25-000181.md) | [15.0](/filings/0001821769-25-000214.md) | [16.4 d](/filings/0001821769-26-000007.md) | [11.7](/filings/0001628280-26-030524.md) | [7.8](/filings/0001628280-26-049808.md) | [5.2](/filings/0001821769-25-000214.md) | [10.5 d](/filings/0001821769-26-000007.md) | [11.3](/filings/0001628280-26-030524.md) | [13.0](/filings/0001628280-26-049808.md) |
| Operating income | $m | [(28.6)](/filings/0001821769-24-000122.md) | [(26.8) d](/filings/0001821769-25-000021.md) | [(31.6)](/filings/0001821769-25-000068.md) | [(31.1)](/filings/0001821769-25-000181.md) | [(29.0)](/filings/0001821769-25-000214.md) | [(39.0) d](/filings/0001821769-26-000007.md) | [(25.3)](/filings/0001628280-26-030524.md) | [(21.7)](/filings/0001628280-26-049808.md) | [(19.4)](/filings/0001821769-25-000214.md) | [(41.4) d](/filings/0001821769-26-000007.md) | [(27.8)](/filings/0001628280-26-030524.md) | [(27.2)](/filings/0001628280-26-049808.md) |
| Income tax | $m | [0.0](/filings/0001821769-24-000122.md) | [(0.5) d](/filings/0001821769-25-000021.md) | [0.1](/filings/0001821769-25-000068.md) | [0.1](/filings/0001821769-25-000181.md) | [0.1](/filings/0001821769-25-000214.md) | [(0.6) d](/filings/0001821769-26-000007.md) | [0.1](/filings/0001628280-26-030524.md) | [0.0](/filings/0001628280-26-049808.md) | [(0.0)](/filings/0001821769-25-000214.md) | [(0.1) d](/filings/0001821769-26-000007.md) | [0.1](/filings/0001628280-26-030524.md) | [0.1](/filings/0001628280-26-049808.md) |
| Net income | $m | [7.5](/filings/0001821769-24-000122.md) | [(32.6) d](/filings/0001821769-25-000021.md) | [(3.7)](/filings/0001821769-24-000064.md) | [(22.3)](/filings/0001821769-24-000094.md) | [(18.7)](/filings/0001821769-24-000122.md) | [(39.9) d](/filings/0001821769-25-000021.md) | [(16.8)](/filings/0001628280-26-049808.md) | [(49.1)](/filings/0001628280-26-049808.md) | [(19.2)](/filings/0001821769-25-000214.md) | [(31.8) d](/filings/0001821769-26-000007.md) | [(33.8)](/filings/0001628280-26-049808.md) | [(228)](/filings/0001628280-26-049808.md) |
| Diluted EPS | $ per share | [0.04](/filings/0001821769-24-000122.md) | not reported | [(0.02)](/filings/0001821769-25-000068.md) | [(0.12)](/filings/0001821769-25-000181.md) | [(0.10)](/filings/0001821769-25-000214.md) | not reported | [(0.09)](/filings/0001628280-26-030524.md) | [(0.25)](/filings/0001628280-26-049808.md) | [(0.09)](/filings/0001821769-25-000214.md) | not reported | [(0.15)](/filings/0001628280-26-030524.md) | [(0.95)](/filings/0001628280-26-049808.md) |
| Basic EPS | $ per share | [0.04](/filings/0001821769-24-000122.md) | not reported | [(0.02)](/filings/0001821769-25-000068.md) | [(0.12)](/filings/0001821769-25-000181.md) | [(0.10)](/filings/0001821769-25-000214.md) | not reported | [(0.09)](/filings/0001628280-26-030524.md) | [(0.25)](/filings/0001628280-26-049808.md) | [(0.09)](/filings/0001821769-25-000214.md) | not reported | [(0.15)](/filings/0001628280-26-030524.md) | [(0.95)](/filings/0001628280-26-049808.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [177](/filings/0001821769-23-000176.md) | [152](/filings/0001821769-25-000021.md) | [129](/filings/0001821769-25-000068.md) | [112](/filings/0001821769-25-000181.md) | [98.3](/filings/0001821769-25-000214.md) | [86.7](/filings/0001821769-26-000007.md) | [75.1](/filings/0001628280-26-030524.md) | [161](/filings/0001628280-26-049808.md) | [151](/filings/0001821769-25-000214.md) | [237](/filings/0001628280-26-049808.md) | [221](/filings/0001628280-26-030524.md) | [557](/filings/0001628280-26-049808.md) |
| Current assets | $m | [215](/filings/0001821769-23-000176.md) | [206](/filings/0001821769-25-000021.md) | [191](/filings/0001821769-24-000064.md) | [165](/filings/0001821769-24-000094.md) | [145](/filings/0001821769-24-000122.md) | [122](/filings/0001821769-26-000007.md) | [108](/filings/0001821769-25-000068.md) | [193](/filings/0001821769-25-000181.md) | [179](/filings/0001821769-25-000214.md) | [260](/filings/0001628280-26-049808.md) | [246](/filings/0001628280-26-030524.md) | [602](/filings/0001628280-26-049808.md) |
| Total assets | $m | [494](/filings/0001821769-23-000176.md) | [486](/filings/0001821769-25-000021.md) | [468](/filings/0001821769-24-000064.md) | [439](/filings/0001821769-24-000094.md) | [419](/filings/0001821769-24-000122.md) | [390](/filings/0001821769-26-000007.md) | [371](/filings/0001821769-25-000068.md) | [449](/filings/0001821769-25-000181.md) | [430](/filings/0001821769-25-000214.md) | [500](/filings/0001628280-26-049808.md) | [481](/filings/0001628280-26-030524.md) | [832](/filings/0001628280-26-049808.md) |
| Current liabilities | $m | [45.4](/filings/0001821769-23-000176.md) | [48.5](/filings/0001821769-25-000021.md) | [42.0](/filings/0001821769-24-000064.md) | [29.0](/filings/0001821769-24-000094.md) | [26.0](/filings/0001821769-24-000122.md) | [21.1](/filings/0001821769-26-000007.md) | [19.3](/filings/0001821769-25-000068.md) | [23.4](/filings/0001821769-25-000181.md) | [22.5](/filings/0001821769-25-000214.md) | [52.1](/filings/0001628280-26-049808.md) | [56.9](/filings/0001628280-26-030524.md) | [27.6](/filings/0001628280-26-049808.md) |
| Total liabilities | $m | [90.6](/filings/0001821769-23-000176.md) | [105](/filings/0001821769-25-000021.md) | [70.0](/filings/0001821769-24-000064.md) | [51.0](/filings/0001821769-24-000094.md) | [38.6](/filings/0001821769-24-000122.md) | [42.0](/filings/0001821769-26-000007.md) | [29.0](/filings/0001821769-25-000068.md) | [60.6](/filings/0001821769-25-000181.md) | [59.2](/filings/0001821769-25-000214.md) | [56.8](/filings/0001628280-26-049808.md) | [61.3](/filings/0001628280-26-030524.md) | [31.0](/filings/0001628280-26-049808.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [403](/filings/0001821769-23-000176.md) | [381](/filings/0001821769-24-000088.md) | [398](/filings/0001821769-25-000214.md) | [388](/filings/0001821769-25-000214.md) | [381](/filings/0001821769-25-000214.md) | [348](/filings/0001628280-26-049808.md) | [342](/filings/0001628280-26-049808.md) | [389](/filings/0001628280-26-049808.md) | [371](/filings/0001821769-25-000214.md) | [444](/filings/0001628280-26-049808.md) | [420](/filings/0001628280-26-049808.md) | [801](/filings/0001628280-26-049808.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.2) d](/filings/0001821769-24-000122.md) | [(23.9) d](/filings/0001821769-25-000021.md) | [(19.8)](/filings/0001821769-25-000068.md) | [(15.1) d](/filings/0001821769-25-000181.md) | [(13.7) d](/filings/0001821769-25-000214.md) | [(10.2) d](/filings/0001821769-26-000007.md) | [(13.5)](/filings/0001628280-26-030524.md) | [(11.2) d](/filings/0001628280-26-049808.md) | [(10.0) d](/filings/0001821769-25-000214.md) | [(8.1) d](/filings/0001821769-26-000007.md) | [(16.4)](/filings/0001628280-26-030524.md) | [(32.0) d](/filings/0001628280-26-049808.md) |
| Capital expenditure | $m | [1.7 d](/filings/0001821769-24-000122.md) | [1.4 d](/filings/0001821769-25-000021.md) | [2.9](/filings/0001821769-25-000068.md) | [2.7 d](/filings/0001821769-25-000181.md) | [0.6 d](/filings/0001821769-25-000214.md) | [0.6 d](/filings/0001821769-26-000007.md) | [0.0](/filings/0001628280-26-030524.md) | [0.7 d](/filings/0001628280-26-049808.md) | [0.7 d](/filings/0001821769-25-000214.md) | [0.0 d](/filings/0001821769-26-000007.md) | [0.4](/filings/0001628280-26-030524.md) | [0.2 d](/filings/0001628280-26-049808.md) |
| Share repurchases | $m | [0.0 d](/filings/0001821769-23-000176.md) | [0.0 d](/filings/0001821769-24-000088.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [138](/filings/0001821769-23-000176.md) | [157](/filings/0001821769-24-000064.md) | [166](/filings/0001821769-24-000094.md) | [186](/filings/0001821769-24-000122.md) | [180](/filings/0001821769-25-000068.md) | [183](/filings/0001821769-25-000181.md) | [185](/filings/0001821769-25-000214.md) | [188](/filings/0001628280-26-030524.md) | [199](/filings/0001628280-26-049808.md) | [213](/filings/0001821769-25-000214.md) | [230](/filings/0001628280-26-030524.md) | [241](/filings/0001628280-26-049808.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 183,457,686 at 2024-08-02, from the cover of the [10-Q filed 2024-08-05](/filings/0001821769-24-000094.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.